Poslední aktualizace :
19/11/2024
vėžio narkotikų   Mitoxantrone dihydrochloride  
Įpurškimas
Tirpalų stabilumas Mišinių stabilumas Stabilumą lemiantys veiksniai Suderinamumas Leidimo būdai Bibliografija pdf
   Cheminė sandara  

Prekinis pavadinimas   Prekinis pavadinimas     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Bluxantron Ekvadoras
Bresnix Meksikas
Ebexantron Austrija
Elsep Prancūzija
Formyxan Ekvadoras, Kolumbija, Meksikas
Genefadrone Graikija
Mitoxgen Argentina
Neotalem Meksikas
Novantron Austrija, Šveicarija, Vokietija
Novantrone Airija, Belgija, Čilė, Danija, Graikija, Ispanija, Italija, Jungtinės Amerikos Valstijos, Jungtiniai Arabų Emyratai, Liuksemburgas, Malaizija, Marokas, Naujojoje Zelandijoje, Norvegija, Pietų Afrikos Respublika, Prancūzija, Rumunija, Slovėnija, Švedija, Tailandas, Turkija, Vengrija
Onkotrone Australija, Didžioji Britanija, Italija, Liuksemburgas, Rumunija, Vokietija
Ralenova Vokietija
Refador Vengrija
Santrone Egiptas, Malaizija
Strimax Ispanija
Xantrosin Belgija
Bibliografija   Įpurškimas   Bibliografija : Mitoxantrone dihydrochloride  
tipas leidinys
3 Žurnalas Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 Žurnalas Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Žurnalas Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Žurnalas Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Žurnalas Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Žurnalas Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Žurnalas Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Žurnalas Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Žurnalas Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Žurnalas Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Žurnalas Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Žurnalas Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Žurnalas Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Žurnalas Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Žurnalas Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
484 Žurnalas Northcott M, Allsopp MA, Powell H, Sewell GJ.
The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged “in use” conditions.
J Clin Pharm Ther 1991 ; 16: 123-129.
492 Žurnalas Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
828 Žurnalas Lecompte D, Bousselet M, Magnam J.
Stability of mitoxantrone (Novantrone*) after dilution in PVC infusions.
J Pharm Clin 1990 ; 9: 159-165.
905 Žurnalas Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Žurnalas Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1317 Žurnalas Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG.
Pharmaceutical aspects of home infusion therapy for cancer patients.
Pharm J 1987 ; 238: 476-478.
1410 Žurnalas Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Žurnalas Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Žurnalas Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 Žurnalas Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 Žurnalas Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Žurnalas Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1730 Žurnalas Björkman S, Roth B.
Chemical compatibility of mitoxantrone and etoposide (VP-16).
Act Pharm Nord 1991 ; 3: 251.
1925 Žurnalas Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Žurnalas Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2344 Laboratorija Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
Ebewe Pharma 2009
3640 Laboratorija Mitoxantrone - Summary of Product Characteristics
Hospira 2013

  Mentions Légales